evan weekli dose therapi video updat
week -- potenti treatment gilead remdesivir safeti
issu novarti beovu posit read-through regeneron top pick market
react global fear spread novel coronaviru back weekli video
help make sens week
overal perform week thursday xbi ibb nbi vs
best perform coverag worst perform galapago
figur weekli ytd perform coverag biotech/ pharma
indic
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau univers toronto figur coverag sector perform weekli ytd
question investor week
rel gilead perform warrant
week share mid-week report compani begun
test broad anti-vir remdesivir potenti treatment diseas
caus novel coronaviru share come back slightli think rel
ralli vs broader market overli amplifi potenti
impact treatment
even remdesivir shown effect treat diseas
expect gilead sell treatment commerci gain past commentari compani
suggest act benefit public health sort profit
view even approv remdesivir unlik chang near-term revenu earn
growth stori share maintain need see meaning chang
trajectori
share strong week
earlier week american societi retin specialist asr highlight
potenti risk vascul seriou variant occlus retin vascul
caus blind associ use novarti beovu per asr memo
incid vascul seriou type total
inject us mean believ retin specialist could stop
use beovu favor eylea consequenti increas near-term assumpt
eylea less like competit beovu
make sens broader sell
hard say weve hit bottom market fear spread
coronaviru extrem impact broader market none
coverag warn miss guidanc suppli chain disruptionsw get
sens still earli assess potenti impact epidem
close watch coverag broader biotech space assess impact
coronaviru name
news updat across coverag
regeneron eylea competitor stumbl rais tp estim week
report american societi retina specialist asr suggest real-world usag
novarti beovu could lead vascul potenti blind caus seriou variant call
occlus retin vascul speak regeneron type side effect never seen
anti-vegf therapi present etiolog rare side effect unknown novarti
start review case data think headlin risk warn asr could
enough significantli slow usag beovu end rais estim eylea addit
revis dupix estim increas tp reiter regeneron top
ulcer coliti preview filgotinib data preview preview ulcer coliti landscap
ahead gilead/galapago phase pivot trial filgotinib uc expect
broadli expect greater util novel oral agent jak anti-integrin etc
treatment uc ibd condit think trial like meet primari endpoint
differenti filgotinib rinvoq jak inhibitor develop challeng
expect filgotinib data
like resembl rinvoq phase data given select
improv upon profil seen xeljanz name safeti overal think posit data consider
impact galapago gilead view opportun filgotinib modest best
across indic ra uc crohn project adjust end-us sale in-
line consensu smaller indic uc unlik chang revenu earn trajectori
gilead reiter under-perform glpg share fairli valu opportun reiter neutral
 sangamo deal announc collabor sangamo develop gene regul
therapi alzheim parkinson neurolog diseas think fit well within
strategi repres lower cost way expand work neurolog
equiti invest sangamo cover secur access gene regul
platform target neurolog diseas agreement also includ right nine undisclos neuro
target pre-clin program thu expect substant updat near-
term despit posit bia toward deal note remain year aducanumab
develop today deal substanti chang near-term view focu
mainli outcom aducanumab sangamo partnership
gilead chatter thursday bloomberg headlin suggest approach
forti seven take-ov bid forti seven could help gilead expand oncolog in-lin w/ recent
commentari manag howev would chang near-term earn revenu
trajectori like see transform transact
gilead coronaviru share trade higher past month report world
organ indic remdesivir may drug coronaviru follow nearli
month out-performance sinc jan vs nbi xbi nearli
bloomberg headlin relat applaud effort help global
pandem believ effort chang underli fundament gilead stori
even remdesivir shown effect highli unlik would significantli
alter near-term revenu earn trajectori share reiter under-perform
impact coronaviru coverag broader market declin coronaviru
concern note compani cover warn guidanc suppli chain issu
fundament these cover compani remain intact moment
nurtec rimegep compet drug acut migrain satsuma
believ oral gepant anti-cgrp could consider competit threat
given nurtec conveni oral administr posit clinic trial data despit potenti
competit landscap believ market support sever compet drug
 nightstar gene therapi recent natur articl report posit outcom x-
link retin pigmentosa xlrp caus mutat rpgr trial patient toler
retin gene therapi dose-depend respons patient back baselin
vision level month procedur dlt phase gene therapi trial
note phase trial choroideremia current on-going
fda launch purpl book fda announc first version on-line databas biolog
product inform week similar fda orang book databas build previou pdf
list biolog product improv searchabl product name type biolog licens
applic bla dose strength licens statu bla number approv date databas
highlight import biolog futur therapi fda commit improv avail
watch come week
co-host call colleagu aj rice public health expert monday
et discuss public health implic help provid clariti
evolv situat surround novel coronaviru outbreak
dial detail follow provid prior call
evan marti biotech pud call seri continu next friday
estimate hiv expert physician
risdiplam approval/launch sma pdufa
gilead filgotinib ph data uc
pemigatinib approv cholangiocarcinoma pdufa
neurocrin opicapon approv parkinson diseas pdufa
regeneron head-to-head data jade compar dupix vs abrocitinib ad
confer retrovirus opportunist infect croi march boston
american academi allergi asthma immunolog aaaai march philadelphia pa
american academi dermatolog aad march denver co
american colleg cardiolog march chicago il
endocrin societi annual meet endo march san francisco ca
charl martineau univers toronto compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori galapago nv glpg
signifi initi assumpt coverag
price rate histori inc gild oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori inc regn oq
charl martineau univers toronto signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
